Jiangsu Hengrui Pharmaceuticals Co.,Ltd (SHA:600276)
China · Delayed Price · Currency is CNY 43.91
+0.68 (1.57%)
Sep 18, 2026, 3:00 PM CST
SHA:600276 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 289,530 | 395,759 | 291,858 | 287,598 | 245,741 | 323,076 | |
Market Cap Growth | -38.01% | 35.60% | 1.48% | 17.03% | -23.94% | -45.40% |
Enterprise Value | 251,280 | 355,894 | 269,604 | 270,642 | 228,393 | 306,010 |
Last Close Price | 43.91 | 59.33 | 45.55 | 44.66 | 37.91 | 49.70 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 37.73 | 51.32 | 46.06 | 66.85 | 62.91 | 71.32 |
Forward PE | 32.42 | 38.99 | 49.34 | 56.94 | 49.45 | 52.14 |
PS Ratio | 9.24 | 12.51 | 10.43 | 12.60 | 11.55 | 12.47 |
PB Ratio | 4.46 | 6.40 | 6.33 | 7.01 | 6.40 | 9.08 |
P/TBV Ratio | 4.73 | 6.67 | 6.58 | 7.27 | 6.59 | 9.35 |
P/FCF Ratio | 51.24 | 47.84 | 53.52 | 46.69 | - | 126.49 |
P/OCF Ratio | 32.45 | 35.22 | 39.32 | 37.63 | 194.22 | 76.58 |
PEG Ratio | 4.77 | 4.98 | 4.11 | 3.47 | 10.27 | 4.78 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 8.02 | 11.25 | 9.63 | 11.86 | 10.74 | 11.81 |
EV/EBITDA Ratio | 29.63 | 40.04 | 37.46 | 55.89 | 63.46 | 71.83 |
EV/EBIT Ratio | 33.45 | 44.01 | 41.63 | 64.81 | 74.65 | 81.29 |
EV/FCF Ratio | 44.47 | 43.02 | 49.44 | 43.94 | - | 119.81 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.00 |
Debt / EBITDA Ratio | 0.01 | 0.01 | 0.02 | 0.02 | 0.37 | 0.04 |
Debt / FCF Ratio | 0.01 | 0.01 | 0.02 | 0.01 | - | 0.06 |
Net Debt / Equity Ratio | -0.60 | -0.66 | -0.54 | -0.51 | -0.43 | -0.52 |
Net Debt / EBITDA Ratio | -4.61 | -4.61 | -3.47 | -4.29 | -4.59 | -4.36 |
Net Debt / FCF Ratio | -6.86 | -4.95 | -4.58 | -3.37 | 22.71 | -7.27 |
Asset Turnover | 0.47 | 0.53 | 0.60 | 0.53 | 0.52 | 0.70 |
Inventory Turnover | 1.60 | 1.68 | 1.64 | 1.50 | 1.44 | 1.80 |
Quick Ratio | 10.62 | 7.38 | 8.62 | 10.74 | 7.36 | 7.72 |
Current Ratio | 11.68 | 8.08 | 9.72 | 12.25 | 8.50 | 8.88 |
Return on Equity (ROE) | 12.46% | 14.31% | 14.55% | 10.77% | 10.31% | 13.51% |
Return on Assets (ROA) | 7.02% | 8.42% | 8.62% | 6.06% | 4.69% | 6.36% |
Return on Invested Capital (ROIC) | 27.08% | 34.20% | 27.67% | 18.16% | 15.12% | 24.01% |
Return on Capital Employed (ROCE) | 11.30% | 12.70% | 13.90% | 10.10% | 7.90% | 10.50% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 2.67% | 1.95% | 2.17% | 1.50% | 1.59% | 1.40% |
FCF Yield | 1.95% | 2.09% | 1.87% | 2.14% | -0.30% | 0.79% |
Dividend Yield | 0.46% | 0.34% | 0.44% | 0.45% | 0.42% | 0.32% |
Payout Ratio | 17.32% | 16.66% | 20.12% | 23.77% | 26.00% | 23.54% |
Buyback Yield / Dilution | -4.76% | -3.13% | -0.15% | 1.20% | -0.36% | 0.18% |
Total Shareholder Return | -4.31% | -2.79% | 0.29% | 1.65% | 0.06% | 0.51% |